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AbstrAct
Vascular endothelial growth factor receptor-2 (VEGFR-2) is an attractive target 
in oncology due to its crucial role in angiogenesis. In this study a DNA vaccine 
coding for human VEGFR-2 was evaluated in healthy mice and dogs, administered 
by intradermal injection and electroporation. In mice, three doses and vaccination 
schedules were evaluated. Cellular immune responses were measured by intracellular 
IFN-gamma staining and a cytotoxicity assay and antibodies by ELISA. Safety was 
assessed by measuring regulatory T cells and myeloid derived suppressor cells and a 
wound healing assay. The vaccine was subsequently evaluated in dogs, which were 
vaccinated three times with 100µg. Cellular immune responses were measured by 
intracellular IFN-gamma staining and antibodies by a flow cytometric assay. In mice, 
maximal cellular responses were observed after two vaccinations with 5µg. Humoral 
responses continued to increase with higher dose and number of vaccinations. No 
abnormalities in the measured safety parameters were observed. The vaccine was 
also capable of eliciting a cellular and humoral immune response in dogs. No adverse 
effects were observed, but tolerability of the electroporation was poor. This study 
will facilitate the evaluation of the vaccine in tumor bearing animals, ranging from 
rodent models to dogs with spontaneous tumors.
IntroductIon
It is well-known that the immune system is capable 
of recognizing tumor cells and to establish a specific long-
term antitumor response. Therefore, vaccination against 
tumor antigens holds great promises in the treatment for 
cancer [1]. However, due to complex interactions between 
tumor cells and the immune system and the problem of 
tolerance, the translation of the theoretical potential of 
tumor vaccines into an effective clinical response has been 
difficult [2]. 
In healthy individuals, vascular endothelial 
growth factor-2 (VEGFR-2) is expressed on virtually 
all endothelial cells as well as on certain other cell 
types including retinal progenitor cells, megakaryocytes 
and pancreatic duct cells. In cancer patients, VEGFR-2 
is strongly overexpressed on tumoral blood vessels 
[3]. VEGFR-2 can thus be classified as a ubiquitous 
tumor antigen. The potential of raising an effective 
immune response against these tumor antigens without 
causing auto-immunity can be explained by the level of 
overexpression in tumors, reaching the threshold for T cell 
recognition and thus breaking immune tolerance [4]. As 
it is difficult to raise a strong immune response against 
self-antigens, xenogeneic vaccination, which involves the 
use of an antigen of a different species, has been proven to 
result in more potent immune responses [5].
VEGFR-2 as vaccine target has some important 
advantages. Tumor cells have grown under the selective 
pressure of the immune system. Evading immune control 
is one of the hallmarks of tumors, with down regulation 
of MHC-1 molecules and resistance to cytotoxic effects 
of immune cells as two common examples [1]. These 
immune evasive strategies acquired during tumor growth 
make tumor cells difficult targets for vaccine strategies. 
Moreover, because of their genetic instability, tumor 
antigens in tumor cells are prone to mutations, which 
leads to escape mutants that further decrease the efficacy 
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of tumor vaccines [1]. Endothelial cells of tumoral blood 
vessels have not acquired immune evasive strategies and 
are genetically stable [6]. They are thus more vulnerable to 
vaccination strategies. Targeting tumor vasculature instead 
of tumor cells directly has proven its value, for instance by 
the success of bevacizumab [3].
Although targeting VEGFR-2 is primarily an 
anti-angiogenic treatment, certain tumors also express 
VEGFR-2, serving as an autocrine growth factor for these 
cells [7]. In these tumor types VEGFR-2 vaccination 
can also induce a direct antitumor effect. Moreover, 
VEGFR-2 is expressed on regulatory T cells (Tregs) 
and myeloid derived suppressor cells (MDSCs) [8, 9]. 
Targeting these cells via VEGFR-2 vaccination can have 
a self-reinforcing effect, as these cells suppress anti-tumor 
immune responses [1]. 
VEGF/VEGFR targeting has been explored 
extensively with different treatment modalities, with some 
of them approved for clinical use [6]. In preclinical studies 
vaccination against VEGFR-2 has also been explored [10]. 
Vaccination has some important advantages. It is more 
specific than small molecule inhibitors and compared to 
monoclonal antibodies the polyclonal antibody response 
evoked by vaccination may have a higher antigen 
neutralizing capacity. Both monoclonal antibodies 
and small molecule inhibitors have to be administered 
frequently, which makes vaccination a much more cost 
efficient therapy [6]. Different vaccine platforms exist. 
DNA vaccination has the advantage that the antigen is 
synthetized intracellularly, leading to a robust cellular 
immune response [11]. Moreover, DNA vaccines often 
make use of plasmids that contain immune stimulating 
unmethylated CpG motives [12]. Electroporation 
mediated delivery of DNA vaccines can further support 
the development of an immune response because the 
limited tissue damage caused by electroporation also 
serves as an adjuvant [13]. Delivery of DNA vaccines via 
electroporation has also the advantage that the vaccine 
manufacture is more economical, uniform and suitable for 
large scale production than when viral or chemical carriers 
are used for the delivery [14, 15]. 
In this study we evaluated in healthy mice and dogs 
the safety and immunogenicity of a xenogeneic VEGFR-2 
DNA vaccine. The DNA vaccine was administered 
as a naked plasmid in combination with needle array 
electroporation. 
results
effect of vaccine dose and vaccination schedule on 
the immune response in mice 
cellular immune response in mice 
To study the influence of the VEGFR-2 DNA 
dose and vaccination schedule on the induction of 
tumor antigen specific cytotoxic T-lymphocytes we 
incubated splenocytes with tumor cells expressing human 
VEGFR-2 at an effector:target ratio of 20:1. Splenocytes 
from vaccinated mice demonstrated significant higher 
cytotoxicity than those from control mice (p = 0.015) 
without a significant effect of the DNA vaccine dose 
(Figure 1). When we tested the effect of the different 
vaccination schedules on the cytotoxic T-lymphocytes 
we found that one boost is superior to none (p = 0.002). 
Overall, there was no significant difference between three 
and two vaccinations, although for 5µg a trend towards 
better response after three vaccinations is visible. After 
co-incubation with splenocytes from mice vaccinated 
at least two times there were on average 52% surviving 
target cells (standard deviation (SD) 14%), compared to 
89% (SD 13%) when co-incubated with splenocytes from 
non-vaccinated mice. There was no difference in response 
towards tumor cells not expressing human VEGFR-2, 
demonstrating a specific response towards the antigen. 
Analysis of IFN-gamma secretion leads to the same 
conclusions (Figure 2). After overnight incubation with a 
murine VEGFR-2 protein there were on average 14% (SD 
5%) IFN-gamma positive lymphocytes in the splenocytes 
of mice that received at least two vaccinations, compared 
to 1% (SD 1%) in splenocytes from non-vaccinated 
mice. Again, no difference in IFN-gamma secretion was 
observed in non-stimulated splenocytes. 
Humoral immune response in mice 
The impact of the VEGFR-2 DNA dose and 
vaccination schedule on the induction of antibodies is 
summarized in Table 1. Both DNA vaccine dose and 
vaccination schedule had a significant impact on antibody 
titer (p < 0.001 and p = 0.003 respectively). Antibody 
responses were undetectable in mice vaccinated with 
the lowest dose (5µg) and for all doses after only one 
vaccination. The highest antibody titers were present 
in serum from mice vaccinated three times with 25µg, 
reaching an antibody titer of 800 in this group. 
safety in mice
Vaccination with DNA encoding human VEGFR-2 
had no effect on normal levels of Tregs (2.38 ± 0.49 in 
non-vaccinated mice versus 2.57 ± 0.51% in vaccinated 
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Figure 1: cytotoxic activity of splenocytes isolated from non-vaccinated and vaccinated mice that received one (prime), 
two (prime + boost), or three (prime + boost + boost) VeGFr-2 dnA vaccinations. Three different DNA vaccine doses (5, 15 
or 25 µg) were tested. Two weeks after the last vaccination splenocytes were collected and their capacity to lyse VEGFR-2 expressing target 
cells was measured. (control indicates non-vaccinated mice, bars represent mean, error bars standard error of the mean, n = 4).
Figure 2: Interferon-gamma response of splenocytes isolated from non-vaccinated and vaccinated mice that received 
one (prime), two (prime + boost), or three (prime + boost + boost) VeGFr-2 dnA vaccinations. Three different DNA 
vaccine doses (5, 15 or 25 µg) were tested. Two weeks after the last vaccination splenocytes were collected and stimulated with murine 
VEGFR-2 protein. Following stimulation the percentage of IFN-gamma positive splenocytes was measured by flow cytometry after 
intracellular cytokine staining. (control indicates non-vaccinated mice, bars represent mean, error bars standard error of the mean).
Oncotarget10908www.impactjournals.com/oncotarget
mice) or MDSCs in the spleen of healthy mice (1.68 ± 
0.35% in non-vaccinated mice versus 1.70 ± 0.32% in 
vaccinated mice). There was also no effect on the mean 
time until wound closure (5 days for both vaccinated and 
non-vaccinated mice, SD 1 day). 
Immunogenicity in dogs
cellular immune response in dogs
Before the start of the vaccination and two weeks 
after each vaccination peripheral blood mononuclear cells 
(PBMCs) were collected from the dogs and stimulated 
with human VEGFR-2. Subsequently, the percentage 
of IFN-gamma positive PBMCs was measured by flow 
cytometry after intracellular staining. After the first and 
second vaccination we could not detect a significant IFN-
gamma response compared to baseline (data not shown). 
However, after the third vaccination (i.e. second boost) 
the percentage of IFN-gamma positive lymphocytes were 
significantly increased with an average of 9% of IFN-
gamma positive lymphocytes (SD 0.05%) compared 
to 4% (SD 0.02%) at baseline (p = 0.04) (Figure 3). No 
change in IFN-gamma secretion in non-stimulated PBMCs 
compared to baseline was present at any time point. 
We also tried to measure the cytotoxic T cell 
response after VEGFR-2 DNA vaccination of dogs by 
co-incubating PBMCs with a canine hemangiosarcoma 
(HSA) cell line. However, at baseline (i.e. before 
vaccination) there was already a considerable cytotoxic 
response of isolated PBMCs towards the canine HSA cell 
line, with only 26% (SD 9%) HSA cells surviving the co-
incubation. No increase in this cytotoxic response was 
observed after the last vaccination (data not shown). This 
demonstrates that the allogeneic nature of the target cells 
already triggered a significant cytotoxic response from 
naïve PBMCs, as previously reported for human PBMCs 
[18]. It is hypothesized that this response is already at 
maximal capacity at baseline explaining no increase after 
vaccination.
Humoral Immune response in dogs
In vaccinated dogs antibody levels against 
VEGFR-2 had significantly increased (relative to baseline 
levels) after the third vaccination (p = 0.03). When looking 
at individual dogs, four out of six dogs had a clear increase 
in antibodies after the second boost (Figure 4). 
tolerability in dogs
The delivery of the very short electric pulses caused 
in all dogs a startle response characterized by withdraw 
Figure 3: Interferon-gamma response of lymphocytes isolated from dogs before vaccination and after a second boost 
with the dnA vaccine. Two weeks after the second boost lymphocytes were collected and stimulated with human VEGFR-2. Following 
stimulating the percentage of IFN-gamma positive lymphocytes was measured by flow cytometry after intracellular cytokine staining. (Bars 
represent mean, error bars standard error of the mean, *p < 0.05).
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movements, vocalization and stress-induced anal sac 
excretion. This only occurred during electroporation, 
which lasted less than one second. Immediately after 
electroporation, dogs exhibited normal behavior and no 
reaction when touching electroporation site could be 
elicited. With the Agilepulse device, actual resistance 
of the tissue during electroporation is measured and 
saved. Hence it could be checked whether the electrodes 
remained in place during the withdraw movements. Based 
on the resistance data we could conclude that the withdraw 
movements did not affect any of the electroporations. This 
is most likely because the total duration of pulses is less 
than a second. Twenty-four hours after electroporation, the 
electroporation site was red and swollen, which evolved 
over two weeks to an epidermal crust. All physical 
parameters (heart rate, respiration rate, temperature, blood 
pressure) remained stable during the vaccination period. 
Figure 4: Humoral immune response in dogs. Left (A): Flow cytometric plots illustrating the evaluation of antibody response by 
the amount of VEGFR-2 expressing target cells bound with antibodies present in serum via a secondary anti-dog IgG antibody (upper: at 
baseline, lower: after the last vaccination of the same dog). Right (b): time course of the antibody response for individual dogs, arrows 
indicate vaccination moments and each colored line represents an individual dog. (HSA = hemangiosarcoma; SSC = side scatter) 
Figure 5: Vaccination schedule in mice. Mice were vaccinated with two weeks interval, two weeks after each vaccination four mice 
were sacrificed to measure cellular and humoral immune response. This vaccination schedule was used to evaluate three different doses of 
the VEGFR-2 DNA vaccine (5, 15 and 25µg).
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dIscussIon
This study demonstrates that a human VEGFR-2 
DNA vaccine, administered in combination with 
electroporation, is capable of inducing a cellular and 
humoral immune response in mice and dogs. The dose 
escalation study in mice demonstrated that it was easier 
to elicit a cellular immune response than a humoral 
immune response. This is in agreement with other studies 
with DNA vaccines and can be explained by the limited 
amounts of proteins released after DNA vaccination, 
which is insufficient for a robust antibody response [19]. 
A very small amount of antigen when presented within 
an antigen presenting cell, either directly by transfection 
or indirectly via cross-presentation, is sufficient to prime 
strong cytotoxic T cell responses [19]. In our mice study 
a cellular immune response was already observed after 
prime-boost vaccination with 5µg pDNA, while higher 
DNA vaccine doses and at least two vaccinations were 
needed to elicit a humoral immune response. VEGFR-2 is 
a transmembrane protein, and thus accessible for both arms 
of the immune system [3]. Indeed, it has been reported that 
both a humoral and a cellular response against VEGFR-2 
can convey antitumor effects [20]. Further evaluation 
of the efficacy of our VEGFR-2 DNA vaccine in tumor 
bearing mice should thus be done with at least 25µg and 
three vaccinations. Vaccination against VEGFR-2 did not 
affect wound healing or normal levels of Tregs or MDSCs 
in healthy mice. Both Tregs and MDSCs significantly 
upregulate their VEGFR-2 expression in response to tumor 
secreted cytokines [8, 9]. It is thus possible that in tumor 
bearing hosts, VEGFR-2 vaccination has a differential 
effect on the percentage of Tregs and MDSCs compared 
to healthy individuals. 
Dose extrapolation of DNA vaccines from mice to 
humans or other animals is difficult. A linear extrapolation 
based on body weight is often used to calculate the dose 
in other species. From such calculations it is frequently 
concluded that the doses are too high to be feasible in 
humans. However, this reasoning is not correct. Firstly, 
correct allometric translation of drug doses should be done 
based on body surface area, which results in drug doses 
0.08 times less than when based on simple conversion 
based on body weight [21]. Secondly, allometric scaling 
of vaccine doses is not relevant, as this is based on 
pharmacokinetic characteristics that do not influence the 
interactions between antigen and immune cells after local 
injection [22]. Many other species specific factors do 
influence vaccine efficiency, that are too complex to allow 
for a scaling formula. Therefore, the DNA vaccine dose for 
dogs in this study (100 µg) was not based on a conversion 
from the results in mice, but on studies that tested 
xenogeneic anti-cancer DNA vaccines in dogs delivered 
with electroporation [23, 24]. The xenogeneic VEGFR-2 
DNA vaccine was successful in inducing a cellular and 
humoral immune response in dogs. A cellular immune 
response was evident by interferon-gamma secretion 
after incubation with human VEGFR-2 protein. The 
immune response against human VEGFR-2 takes more 
time to develop in dogs compared to mice, with a clear 
response only after three vaccinations. This timeframe 
is in agreement with other studies with DNA vaccines 
in dogs [23, 24]. Our xenogeneic DNA vaccine is based 
on human VEGFR-2. Human VEGFR-2 shows a higher 
homology with canine than with murine VEGFR-2 (93% 
versus 86%). This may explain the higher immunogenicity 
of our vaccine in mice. 
The normal levels of Tregs and MDSCs, wound 
healing in healthy mice and physiological parameters 
(heart rate, respiration rate, temperature and blood 
pressure) in healthy dogs are not influenced by the 
vaccine. This indicates that no acute side effects occur 
after administration of our VEGFR-2 DNA vaccine. 
The tolerability of the electroporation on butorphanol 
sedated dogs in combination with local anesthesia is poor. 
As humans treated with the same protocol report good 
tolerability of electroporation and given the nature of 
reactions of the dogs, responses are believed to come from 
startling more than pain [25, 26]. Based on the reaction of 
the dogs one may consider to use higher levels of sedation 
or even anesthesia before electroporation. Because of the 
very short duration of the entire procedure and based on 
evaluation of experienced veterinarians supervising the 
experiment this is not ethically imposed, considering 
discomfort caused by additional manipulations and 
recovery associated with deep sedation or anesthesia. 
However, since the safety of the operators is also an aspect 
that has to be taken into account, higher levels of sedation 
are in our opinion advised. The inflammation and limited 
tissue damage observed at the vaccination site illustrates 
the adjuvant effect of electroporation and did not impact 
the dogs’ welfare in any way. 
Different DNA vaccines targeting VEGFR-2 have 
been evaluated in the past. This wide interest in VEGFR-2 
vaccination demonstrates the potential of this approach. 
The majority of studies with VEGFR-2 DNA vaccines 
used a viral, bacterial or chemical vector to facilitate the 
delivery [17, 20, 27-33]. Uniform large scale production 
is difficult with chemical and biological vectors, making 
clinical use outside a research context challenging [14, 
15]. Biological vectors also raise safety concerns [34]. 
Vaccination with naked plasmid is evaluated in three 
research papers [35-37]. Transfection efficiency of naked 
plasmid however is very low, making this approach far 
from optimal. However, when naked plasmid is delivered 
by the aid of a physical gene delivery method it is possible 
to combine the advantage of industrial suitable vaccine 
manufacturing with high transfection efficiency [38]. 
Moreover, physical gene delivery methods lack vector 
related toxicity issues. Electroporation mediated delivery 
of a VEGFR-2 DNA vaccine has only been evaluated 
once in a preclinical setting [39]. However, the vaccine in 
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this study was developed to include only B cell epitopes, 
excluding cellular immune responses, whereas our 
vaccine is able to elicit both humoral and cellular immune 
responses. 
As the immunogenicity and safety of this xenogeneic 
VEGFR-2 DNA vaccine is demonstrated in dogs and mice, 
the next step is the evaluation of its efficacy in cancer 
bearing animals. Spontaneously arising tumors in dogs 
can be a very valuable intermediate model, potentially 
limiting the now tremendous amount of negative phase 
I trials in human patients because of the low predictive 
power of rodent models [40]. Many tumors in dogs share 
biological, histological and clinical characteristics with 
their human counterparts and responses to treatment are 
very similar. Genetic research has revealed that tumors 
in humans and dogs undergo nearly identical genetic 
changes. An additional advantage of dogs is their body 
size, allowing surgical interventions, medical imaging 
and tissue/blood sampling much like in human patient 
[41]. Several tumor vaccines have first been evaluated 
in canine patients, followed by a clinical trial in humans 
[42-45]. The evaluation of tumor vaccines in clinical 
trials with dogs can also lead to licensing of the vaccine 
for veterinary use. The licensing of Oncept, a xenogeneic 
DNA vaccine encoding human tyrosinase for the treatment 
of melanoma in dogs has led to its widespread use in 
veterinary oncology [46]. Similar to humans VEGFR-2 
overexpression is confirmed in numerous canine cancer 
types [47-55]. In conclusion, our data and the many 
reports on VEGFR-2 will facilitate the evaluation of our 
xenogeneic VEGFR-2 DNA vaccine in tumor bearing 
animals, ranging from preliminary rodent models to highly 
translational models of spontaneous tumors in pet dogs. 
MAterIAl And MetHods
tumor cell lines and VeGFr-2 plasmid
The B16-F10 tumor cell line was a kind gift from 
Johan Grooten (Department of Biomedical Molecular 
Biology, Ghent University, Belgium) and was stably 
transduced with luciferase as described earlier [16]. Briefly, 
retroviral vectors encoding luciferase were produced in 
HEK293T cells by calcium phosphate transfection. Virions 
were harvested after 48 and 72h, filtered and concentrated 
by ultracentrifugation. Transduction the B16-F10 cells 
was performed in the presence of 8 µg/ml polybrene and 
transfection efficiency was evaluated by bioluminescence. 
The canine hemangiosarcoma (HSA) cell line was a kind 
gift of Douglas Thamm (College of Veterinary Medicine 
and Biomedical Sciences, Colorado State University, 
USA). These cells were grown in Dulbecco’s modified 
Eagle’s medium, supplemented with 10% fetal calf serum, 
100 mg/ml streptomycin, 100 IU/ml penicillin and 1 
mmol/ml L-glutamine (Invitrogen, Carlsbad, CA, USA). 
The plasmid encoding human VEGFR-2 was purchased 
form Invivogen (Toulouse, France; pUNO1-hFLK1(mb)). 
Purification of the plasmids was done with the EndoFree 
Giga kit, following the instructions of the manufacturer 
(Qiagen, Valencia, CA, USA). 
dnA vaccine doses and vaccination schedules in 
mice
The vaccination experiments in mice were approved 
by the ethical committee of the Faculty of Veterinary 
Medicine (Ghent University; EC2013/77). Healthy 
C57BL/6JRj mice of 8 weeks old were used for this 
optimization study (Janvier Breeding Center, Le Genest 
St. Isle, France). Three doses (5µg, 15µg and 25µg) and 
three vaccination schedules (prime, prime-boost, prime-
boost-boost) were evaluated with 4 mice in each group 
(Figure 5). A group of untreated mice served as control. 
The VEGFR-2 plasmid was injected intradermally in 20µl 
calcium and magnesium free phosphate buffered saline 
(PBS; Invitrogen) followed by electroporation with the 
BTX Agilepulse device (Harvard apparatus, Holliston, 
MA, USA) using 4 mm gap needle electrodes (2 pulses 
of 450 V with a pulse duration of 0.05 ms and a 300 
ms interval, followed by 8 pulses of 100 V with a pulse 
duration of 10 ms and a 300 ms interval). Mice were 
anesthetized with isoflurane during this procedure. The 
interval between the vaccinations was 2 weeks and mice 
were euthanized 2 weeks after the last vaccination. 
Assessing cellular immune response in vaccinated 
mice
Splenocytes were isolated two weeks after the 
last vaccination. To assess cytotoxic response to cells 
expressing the target, splenocytes were co-incubated with 
bioluminescent B16-F10 melanoma cells that were in vitro 
electroporated with a plasmid encoding human VEGFR-2. 
Electroporation was performed in 2mm cuvettes with the 
table 1: effect of VeGFr-2 dnA vaccine dose and vaccination schedule on 
VeGFr-2 antibody titers. All four mice within each group had the same antibody titer. 
Prime Prime + boost Prime + boost + boost
5µg <4 <4 <4
15µg <4 4 100
25µg <4 400 800
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BTX ECM 830 device (Harvard apparatus, Holliston, MA, 
USA). Two pulses of 140 V with a pulse duration of 5 ms 
and 100 ms interval were used. As a control for specificity 
to the VEGFR-2 target, B16-F10 melanoma cells that 
were mock electroporated were also included. Absence 
of natural VEGFR-2 expression on the B16-F10 cells and 
induction of expression after electroporation were assessed 
by flow cytometry with a rabbit antibody that binds 
VEGFR-2 and an Alexafluor-688 conjugated secondary 
goat anti-rabbit antibody (Abcam, Cambrige, UK). After 
transfection, human VEGFR-2 was expressed on 78% of 
the tumor cells. To measure the tumor killing capacity of 
lymphocytes from vaccinated and non-vaccinated mice we 
incubated 2x105 splenocytes with 104 B16-F10 cells. After 
24 hours the bioluminescent signal, which is related to the 
number of living cells, was measured with an IVIS lumina 
II (Perkin-Elmer, Zaventem, Belgium).
Additionally, the IFN-gamma response was also 
measured. In more detail, 106 splenocytes were stimulated 
overnight with 2µg of murine VEGFR-2 protein (Bio-
Connect, Te Huissen, The Netherlands). Subsequently, 
brefeldin A was added and after 4 hours the cells were 
incubated overnight in fixation buffer (ImTec Diagnostics, 
Antwerp, Belgium). The following day the cells were 
permeabilized and the intracellular staining of IFN-gamma 
was performed with an APC-conjugated anti-IFN-gamma 
antibody (Imtec Diagnostics). The cells were analyzed 
with an Accuri C6 flow cytometer (BD Biosciences, 
Erembodegem, Belgium) and events in the permeabilized 
lymphocyte gate were selected for analysis. Controls for 
specificity of the cytokine response were assessed by 
including non-stimulated splenocytes in the analysis. 
Assessment humoral immune response in 
vaccinated mice
Blood was collected 2 weeks after the last 
vaccination of each vaccination schedule by cardiac 
puncture under terminal anesthesia. Blood was centrifuged 
(10min, 3000g, Eppendorf centrifuge) and serum was 
collected and stored at -80°C until analysis. Microtiter 
plates were coated overnight with 1µg murine VEGFR-2 
protein in coating buffer and loaded with serial dilutions 
of serum in ELISA assay diluent for 2 hours (Imtec 
Diagnostics). After washing, a HRP-conjugated anti-
mouse IgG antibody was added, followed by development 
with TMB substrate and measuring absorbance with a 
microplate reader at 450nm (ImTec Diagnostics). The 
titer was determined as the limiting dilution with a signal 
exceeding mean plus twice the standard deviation of the 
signal from control samples (non-vaccinated mice). 
Assessment of regulatory t cells and Mdscs 
levels 
As VEGFR-2 expression is reported on Tregs 
and MDSCs, the effect of vaccination on normal levels 
of these cells was assessed as a measure of safety. 
Splenocytes were isolated when mice were sacrificed and 
the percentage of Tregs and MDSCs were measured by 
flow cytometry. Regulatory T cells were stained with a 
FITC-conjugated anti-CD25 antibody, an APC-conjugated 
CD4 antibody and a PE-conjugated anti-FoxP3 antibody 
after fixation and permeabilization with commercial 
buffers (Ebioscience, Vienna, Austria). MDSCs were 
stained with a FITC-conjugated anti-CD11b antibody and 
a PE-conjugated anti-Gr1 antibody (Ebioscience). The 
cells were analyzed with an Accuri C6 flow cytometer and 
events in the lymphocyte gate were selected for analysis. 
Color compensation was based on fluorescence minus one 
(FMO) controls. 
Assessment of wound healing in vaccinated mice
To further assess safety of VEGFR-2 vaccination, 
a wound healing assay was performed. Two circular 
full-thickness dermal wounds were created between the 
shoulder blades with a 2-mm punch biopter one week after 
the last vaccination. These wounds were allowed to heal 
spontaneously and the days until macroscopic closure of 
the wound were determined, as described earlier.[17] 
Vaccination of dogs
The vaccination experiments in dogs were approved 
by the ethical committee of the Faculty of Veterinary 
Medicine (Ghent University; EC2013/40). Six laboratory 
Beagle dogs were vaccinated three times with 100µg of 
human VEGFR-2 plasmid dissolved in 100µl magnesium 
and calcium free PBS. The vaccine was injected 
intradermally followed by electroporation with the BTX 
Agilepulse device (2 pulses of 450 V with a pulse duration 
of 0.05 ms and a 0.2 ms interval, followed by 8 pulses of 
100 V with a pulse duration of 10 ms and a 20 ms interval; 
Harvard apparatus). Dogs were sedated by intravenous 
injection of 0.2mg/kg butorphanol (Vetergesic, Alstoe 
Limited, York, UK). Local anesthesia was obtained 
by subcutaneous injection of 0.5ml of lidocaine 2% 
(Xylocaïne, Recipharm Monts, Monts, France) at the 
vaccination site. 
Assessment of cellular immune response in 
vaccinated dogs
Blood was collected before each vaccination and 
two weeks after each vaccination. Blood was collected 
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in EDTA tubes and peripheral blood mononuclear cells 
(PBMCs) were isolated by centrifugation with Ficoll-
Paque 1.007g/ml (Invitrogen). The canine HSA cell line 
was used to assess a cytotoxic response against VEGFR-2 
expressing cells. Expression of VEGFR-2 by these cells 
was confirmed with an anti-VEGFR-2 antibody and a 
secondary Alexa fluor 688-conjugated goat anti-rabbit 
antibody (both from Abcam). Subsequently, the canine 
HSA cells were in vitro transfected with eGFP via 
electroporation with the BTX device. A cytotoxicity assay 
was performed by incubating 2x105 PBMCs with 104 
eGFP transfected HSA cells and 24 hours later the number 
of eGFP expressing cells was analyzed by flow cytometry 
as a measure of PBMCs mediated killing of VEGFR-2 
positive cells. PBMCs obtained before vaccination served 
as controls.
Additionally, the IFN-gamma response was 
measured after overnight incubation of 106 PBMCs with 
2µg human VEGFR-2 protein, as a recombinant canine 
VEGFR-2 protein is not available (Acro Biosystems, 
London, UK). Subsequently, brefeldin A was added 
followed after 4 hours by overnight incubation in 
fixation buffer (Ebioscience).The next day, PBMCs 
were stained with a FITC-conjugated anti-IFN-gamma 
antibody after permeabilization with a commercial buffer 
(Life Technologies, Ghent, Belgium). The cells were 
analyzed with an Accuri C6 flow cytometer and events 
in the permeabilized lymphocyte gate were selected for 
analysis. Controls for specificity of the cytokine response 
were assessed by including non-stimulated PBMCs in the 
analysis.
Assessment of the humoral immune response in 
vaccinated dogs
Plasma was collected two weeks after each 
vaccination. HSA tumor cells were washed and 
resuspended in 50µl of diluted plasma (1/8 dilution in 
FACS buffer, Imtec Diagnostics). Cells were incubated 
for one hour at 37°C and 5% CO
2
. Subsequently the cells 
were washed and stained with APC-conjugated anti-dog 
IgG antibodies (Imtec Diagnostics) and the number of 
positive cells was analyzed via flow cytometry. Control 
for specificity of staining included HSA cells that were 
not incubated with plasma and stained with the secondary 
antibodies.
Assessment of tolerability and safety of the 
vaccination in dogs
As this is the first time that the Agilepulse 
was used for electroporation of dogs, an important 
outcome measurement was also the tolerability to the 
electroporation. Acute stress and pain signals during the 
electroporation as well as the aspect and sensitivity of 
the vaccination site the days after electroporation were 
monitored. A thorough physical examination including 
Doppler blood pressure monitoring was performed the 
week after each vaccination to assess safety of the vaccine. 
statistics
Data were analyzed with the SPSS software version 
19 (IBM, Brussels, Belgium). The effect of DNA vaccine 
dose and vaccination schedule on the cytotoxicity and 
IFN-gamma secretion of murine splenocytes were 
analyzed with a general linear model. The effect of DNA 
vaccine dose and vaccination schedule on antibody titers 
in serum of mice were analyzed with an exact linear by 
linear association test. The effect of vaccination on IFN-
gamma secretion of canine PBMCs was analyzed with a 
repeated measures ANOVA. The effect of vaccination on 
antibody bound HSA cells were analyzed with the non-
parametric Friedman test. For post hoc tests, correction 
for multiple comparisons was performed with the Tukey 
method.
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